HighVista Strategies’s Novavax NVAX Stock Holding History

HighVista Strategies’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,978	Closed	-$1.03M	–	100
2021 Q3	$1.03M	Sell	4,978 -123	-2%	-$27.1K	0.68%	49
2021 Q2	$1.08M	Buy	5,101 +1,760	+53%	+$322K	0.77%	19
2021 Q1	$606K	Sell	3,341 -2,381	-42%	-$474K	0.45%	58
2020 Q4	$638K	Buy	+5,722	New	+$608K	0.41%	60

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HighVista Strategies's NVAX Position: Q4 2021 in Review

HighVista Strategies sold out of Novavax (NVAX) in Q4 2021, closing a stake of 4,978 shares — an estimated $1.03M sold.

HighVista Strategies first reported a position in NVAX in Q4 2020 and held it in 4 quarters. The position peaked at $1.08M in Q2 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

HighVista Strategies reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
HighVista Strategies sold 4,978 Novavax shares in Q4 2021, an estimated $1.03M.
HighVista Strategies first reported a position in Novavax in Q4 2020 and held it in 4 quarters.
HighVista Strategies's Novavax position peaked at $1.08M in Q2 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.